

Wet Age Related Macular Degeneration (AMD) Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/W54F50D54B0DEN.html>

Date: March 2022

Pages: 63

Price: US\$ 3,250.00 (Single User License)

ID: W54F50D54B0DEN

Abstracts

Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.

This report contains market size and forecasts of Wet Age Related Macular Degeneration (AMD) in Global, including the following market information:

Global Wet Age Related Macular Degeneration (AMD) Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Wet Age Related Macular Degeneration (AMD) market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Wet Age-Related Macular Degeneration (Wet AMD) Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Wet Age Related Macular Degeneration (AMD) include Novartis International (Switzerland), Bayer (Germany), Acucela (US), Neurotech

Pharmaceuticals (US), Ophthotech (US), GlaxoSmithKline (US), Alimera Sciences (US), StemCell (Canada) and F. Hoffmann-La Roche (Switzerland), etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Wet Age Related Macular Degeneration (AMD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Wet Age Related Macular Degeneration (AMD) Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Wet Age Related Macular Degeneration (AMD) Market Segment Percentages, by Type, 2021 (%)

Wet Age-Related Macular Degeneration (Wet AMD)

Dry Age-Related Macular Degeneration (Dry AMD)

Global Wet Age Related Macular Degeneration (AMD) Market, by Age, 2017-2022, 2023-2028 (\$ millions)

Global Wet Age Related Macular Degeneration (AMD) Market Segment Percentages, by Age, 2021 (%)

Above 75 Years

Above 60 Years

Above 40 Years

Global Wet Age Related Macular Degeneration (AMD) Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Wet Age Related Macular Degeneration (AMD) Market Segment Percentages,

By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Wet Age Related Macular Degeneration (AMD) revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Wet Age Related Macular Degeneration (AMD) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis International (Switzerland)

Bayer (Germany)

Acucela (US)

Neurotech Pharmaceuticals (US)

Ophthotech (US)

GlaxoSmithKline (US)

Alimera Sciences (US)

StemCell (Canada)

F. Hoffmann-La Roche (Switzerland)

Regeneron Pharmaceutical (US)

Allergan (Ireland)

Adverum Biotechnologies (US)

Gilead Sciences (US)

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Wet Age Related Macular Degeneration (AMD) Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Age
- 1.3 Global Wet Age Related Macular Degeneration (AMD) Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL WET AGE RELATED MACULAR DEGENERATION (AMD) OVERALL MARKET SIZE

- 2.1 Global Wet Age Related Macular Degeneration (AMD) Market Size: 2021 VS 2028
- 2.2 Global Wet Age Related Macular Degeneration (AMD) Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Wet Age Related Macular Degeneration (AMD) Players in Global Market
- 3.2 Top Global Wet Age Related Macular Degeneration (AMD) Companies Ranked by Revenue
- 3.3 Global Wet Age Related Macular Degeneration (AMD) Revenue by Companies
- 3.4 Top 3 and Top 5 Wet Age Related Macular Degeneration (AMD) Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Wet Age Related Macular Degeneration (AMD) Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Wet Age Related Macular Degeneration (AMD) Players in Global Market
 - 3.6.1 List of Global Tier 1 Wet Age Related Macular Degeneration (AMD) Companies

3.6.2 List of Global Tier 2 and Tier 3 Wet Age Related Macular Degeneration (AMD) Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Wet Age Related Macular Degeneration (AMD) Market Size Markets, 2021 & 2028

4.1.2 Wet Age-Related Macular Degeneration (Wet AMD)

4.1.3 Dry Age-Related Macular Degeneration (Dry AMD)

4.2 By Type - Global Wet Age Related Macular Degeneration (AMD) Revenue & Forecasts

4.2.1 By Type - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2022

4.2.2 By Type - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2023-2028

4.2.3 By Type - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Wet Age Related Macular Degeneration (AMD) Market Size, 2021 & 2028

5.1.2 Above 75 Years

5.1.3 Above 60 Years

5.1.4 Above 40 Years

5.2 By Age - Global Wet Age Related Macular Degeneration (AMD) Revenue & Forecasts

5.2.1 By Age - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2022

5.2.2 By Age - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2023-2028

5.2.3 By Age - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Wet Age Related Macular Degeneration (AMD) Market Size,

2021 & 2028

6.2 By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue & Forecasts

6.2.1 By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2022

6.2.2 By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2023-2028

6.2.3 By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028

6.3.2 US Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.3.3 Canada Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.3.4 Mexico Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028

6.4.2 Germany Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.4.3 France Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.4.4 U.K. Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.4.5 Italy Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.4.6 Russia Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.4.7 Nordic Countries Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.4.8 Benelux Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028

6.5.2 China Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.5.3 Japan Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.5.4 South Korea Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.5.5 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.5.6 India Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Wet Age Related Macular Degeneration (AMD)

Revenue, 2017-2028

6.6.2 Brazil Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.6.3 Argentina Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028

6.7.2 Turkey Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.7.3 Israel Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.7.4 Saudi Arabia Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

6.7.5 UAE Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Novartis International (Switzerland)

7.1.1 Novartis International (Switzerland) Corporate Summary

7.1.2 Novartis International (Switzerland) Business Overview

7.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Major Product Offerings

7.1.4 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)

7.1.5 Novartis International (Switzerland) Key News

7.2 Bayer (Germany)

7.2.1 Bayer (Germany) Corporate Summary

7.2.2 Bayer (Germany) Business Overview

7.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Major Product Offerings

7.2.4 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)

7.2.5 Bayer (Germany) Key News

7.3 Acucela (US)

7.3.1 Acucela (US) Corporate Summary

7.3.2 Acucela (US) Business Overview

7.3.3 Acucela (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings

7.3.4 Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)

7.3.5 Acucela (US) Key News

7.4 Neurotech Pharmaceuticals (US)

7.4.1 Neurotech Pharmaceuticals (US) Corporate Summary

7.4.2 Neurotech Pharmaceuticals (US) Business Overview

7.4.3 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD)

Major Product Offerings

7.4.4 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD)

Revenue in Global Market (2017-2022)

7.4.5 Neurotech Pharmaceuticals (US) Key News

7.5 Ophthotech (US)

7.5.1 Ophthotech (US) Corporate Summary

7.5.2 Ophthotech (US) Business Overview

7.5.3 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings

7.5.4 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)

7.5.5 Ophthotech (US) Key News

7.6 GlaxoSmithKline (US)

7.6.1 GlaxoSmithKline (US) Corporate Summary

7.6.2 GlaxoSmithKline (US) Business Overview

7.6.3 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings

7.6.4 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)

7.6.5 GlaxoSmithKline (US) Key News

7.7 Alimera Sciences (US)

7.7.1 Alimera Sciences (US) Corporate Summary

7.7.2 Alimera Sciences (US) Business Overview

7.7.3 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings

7.7.4 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)

7.7.5 Alimera Sciences (US) Key News

7.8 StemCell (Canada)

7.8.1 StemCell (Canada) Corporate Summary

7.8.2 StemCell (Canada) Business Overview

7.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Major Product Offerings

7.8.4 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)

- 7.8.5 StemCell (Canada) Key News
- 7.9 F. Hoffmann-La Roche (Switzerland)
 - 7.9.1 F. Hoffmann-La Roche (Switzerland) Corporate Summary
 - 7.9.2 F. Hoffmann-La Roche (Switzerland) Business Overview
 - 7.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
 - 7.9.4 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
 - 7.9.5 F. Hoffmann-La Roche (Switzerland) Key News
- 7.10 Regeneron Pharmaceutical (US)
 - 7.10.1 Regeneron Pharmaceutical (US) Corporate Summary
 - 7.10.2 Regeneron Pharmaceutical (US) Business Overview
 - 7.10.3 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
 - 7.10.4 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
 - 7.10.5 Regeneron Pharmaceutical (US) Key News
- 7.11 Allergan (Ireland)
 - 7.11.1 Allergan (Ireland) Corporate Summary
 - 7.11.2 Allergan (Ireland) Business Overview
 - 7.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
 - 7.11.4 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
 - 7.11.5 Allergan (Ireland) Key News
- 7.12 Adverum Biotechnologies (US)
 - 7.12.1 Adverum Biotechnologies (US) Corporate Summary
 - 7.12.2 Adverum Biotechnologies (US) Business Overview
 - 7.12.3 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
 - 7.12.4 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
 - 7.12.5 Adverum Biotechnologies (US) Key News
- 7.13 Gilead Sciences (US)
 - 7.13.1 Gilead Sciences (US) Corporate Summary
 - 7.13.2 Gilead Sciences (US) Business Overview
 - 7.13.3 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
 - 7.13.4 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue

in Global Market (2017-2022)

7.13.5 Gilead Sciences (US) Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Wet Age Related Macular Degeneration (AMD) Market Opportunities & Trends in Global Market

Table 2. Wet Age Related Macular Degeneration (AMD) Market Drivers in Global Market

Table 3. Wet Age Related Macular Degeneration (AMD) Market Restraints in Global Market

Table 4. Key Players of Wet Age Related Macular Degeneration (AMD) in Global Market

Table 5. Top Wet Age Related Macular Degeneration (AMD) Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Wet Age Related Macular Degeneration (AMD) Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Companies, 2017-2022

Table 8. Global Companies Wet Age Related Macular Degeneration (AMD) Product Type

Table 9. List of Global Tier 1 Wet Age Related Macular Degeneration (AMD) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Wet Age Related Macular Degeneration (AMD) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Wet Age Related Macular Degeneration (AMD) Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Wet Age Related Macular Degeneration (AMD) Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Age – Global Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Age - Wet Age Related Macular Degeneration (AMD) Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Age - Wet Age Related Macular Degeneration (AMD) Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue

(US\$, Mn), 2017-2022

Table 19. By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2023-2028

Table 30. Novartis International (Switzerland) Corporate Summary

Table 31. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 32. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 33. Bayer (Germany) Corporate Summary

Table 34. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 35. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 36. Acucela (US) Corporate Summary

Table 37. Acucela (US) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 38. Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 39. Neurotech Pharmaceuticals (US) Corporate Summary

Table 40. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 41. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 42. Ophthotech (US) Corporate Summary

Table 43. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 44. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 45. GlaxoSmithKline (US) Corporate Summary

Table 46. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 47. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 48. Alimera Sciences (US) Corporate Summary

Table 49. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 50. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 51. StemCell (Canada) Corporate Summary

Table 52. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 53. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 54. F. Hoffmann-La Roche (Switzerland) Corporate Summary

Table 55. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 56. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 57. Regeneron Pharmaceutical (US) Corporate Summary

Table 58. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 59. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 60. Allergan (Ireland) Corporate Summary

Table 61. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 62. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 63. Adverum Biotechnologies (US) Corporate Summary

Table 64. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 65. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

Table 66. Gilead Sciences (US) Corporate Summary

Table 67. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Product Offerings

Table 68. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Wet Age Related Macular Degeneration (AMD) Segment by Type in 2021
- Figure 2. Wet Age Related Macular Degeneration (AMD) Segment by Age in 2021
- Figure 3. Global Wet Age Related Macular Degeneration (AMD) Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Wet Age Related Macular Degeneration (AMD) Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Wet Age Related Macular Degeneration (AMD) Revenue in 2021
- Figure 8. By Type - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
- Figure 9. By Age - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
- Figure 12. US Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
- Figure 16. Germany Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn),

2017-2028

Figure 21. Nordic Countries Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028

Figure 24. China Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 28. India Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028

Figure 30. Brazil Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028

Figure 33. Turkey Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Wet Age Related Macular Degeneration (AMD) Revenue, (US\$, Mn), 2017-2028

Figure 37. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Wet Age Related Macular Degeneration (AMD) Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/W54F50D54B0DEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/W54F50D54B0DEN.html>